➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Express Scripts
Medtronic
AstraZeneca
Boehringer Ingelheim

Last Updated: May 28, 2020

DrugPatentWatch Database Preview

REZULIN Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Rezulin, and what generic alternatives are available?

Rezulin is a drug marketed by Pfizer Pharms and is included in one NDA.

The generic ingredient in REZULIN is troglitazone. Additional details are available on the troglitazone profile page.

Drug patent expirations by year for REZULIN
Recent Clinical Trials for REZULIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
NovartisPhase 2

See all REZULIN clinical trials

Synonyms for REZULIN
(+-)-all-rac-5-(p-((6-Hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy)benzyl)-2,4-thiazolidinedione
(+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione
(5R)-5-[[4-[[(2S)-6-hydroxy-2,5,7,8-tetramethyl-chroman-2-yl]methoxy]phenyl]methyl]thiazolidine-2,4-dione
18524-EP2269989A1
18524-EP2270011A1
18524-EP2272825A2
18524-EP2272841A1
18524-EP2275414A1
18524-EP2295409A1
18524-EP2298742A1
18524-EP2301936A1
18524-EP2305219A1
18524-EP2305648A1
18524-EP2308847A1
18524-EP2314576A1
18524-EP2314588A1
2,4-Thiazolidinedione, 5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy)phenyl)methyl)-
2,4-thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-
2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]- (9CI)
322T877
5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione)
5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy)benzyl)thiazolidine-2,4-dione
5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione
5-[(4-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]oxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione
5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1- benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazlidinedione
5-[[4-[(3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione
5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-[[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-[4-(6-Hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]-2,4-dioxothiazolidine
5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine -2,4-dione
5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
5-{4-(6-hydroxy-2, 5, 7, 8-tetramethylchroman-2-yl-methoxy) benzyl) thiazolidine-2,4-dione
5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2h-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidin-2,4-dion
5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione
97322-87-7
AB00643330-02
AB0125513
AK307955
AKOS000281116
AKOS024457434
API0004529
AS-56378
BCP06753
BDBM50088494
BDBM50101974
BG0468
BRD-A13084692-001-02-5
BRN 4338399
C-22371
C24H27NO5S
CAS-97322-87-7
CC-35518
CCG-208125
CCRIS 8969
CHEBI:9753
CHEMBL3542292
CI 991
CI-991
CS 045
CS-045
CS-1634
CS045
CTK7H5564
D00395
DB-057670
DB00197
DSSTox_CID_3719
DSSTox_GSID_23719
DSSTox_RID_77162
DTXSID8023719
FT-0630994
GP8940
GR 92132X
GR-92132X
GR92132X
GTPL2693
GXPHKUHSUJUWKP-UHFFFAOYSA-N
HMS2089D22
HMS2093D04
HMS3649G12
HMS3713D08
HSCI1_000037
HY-50935
K752
KS-00001DVG
LS-151313
MLS006010817
NCGC00161599-01
NCGC00161599-02
NCGC00161599-03
NCGC00161599-04
NCGC00161599-05
NCGC00161599-06
NCGC00161599-07
NCGC00161599-08
NCGC00161599-09
NCGC00161599-11
NCGC00164445-01
NCGC00254440-01
Noscal
Prelay
Q7844989
Rezulin (TN)
Romglizone
Romozin
s8432
SC-46000
SCHEMBL4959
SMP2_000224
SMR001550129
Spectrum5_001973
SR-05000000454
SR-05000000454-2
SR-05000000454-3
SR-05000000454-5
Tox21_112119
Tox21_112119_1
Tox21_300470
troglitazona
troglitazone
Troglitazone (CS-045)
Troglitazone (JAN/USAN/INN)
Troglitazone [USAN:BAN:INN]
Troglitazone [USAN:INN:BAN]
Troglitazone, >=98% (HPLC)
troglitazonum
UPCMLD-DP017
UPCMLD-DP017:001
UPCMLD-DP017:002
VA11909

US Patents and Regulatory Information for REZULIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-001 Jan 29, 1997 DISCN No No   Start Trial   Start Trial   Start Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-003 Aug 4, 1997 DISCN No No   Start Trial   Start Trial   Start Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-002 Jan 29, 1997 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for REZULIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-002 Jan 29, 1997   Start Trial   Start Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-003 Aug 4, 1997   Start Trial   Start Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-001 Jan 29, 1997   Start Trial   Start Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-001 Jan 29, 1997   Start Trial   Start Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-003 Aug 4, 1997   Start Trial   Start Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-002 Jan 29, 1997   Start Trial   Start Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-001 Jan 29, 1997   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for REZULIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0139421 SPC/GB97/084 United Kingdom   Start Trial PRODUCT NAME: TROGLITAZONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK 10949/0277 19970729; UK 10949/0278 19970729; UK 10949/0279 19970729; UK 06384/0005 19970729; UK 06384/0006 19970729; UK 06384/0007 19970729
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Express Scripts
Medtronic
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.